Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 4/20 | 0.40 |
| ▸ | ACVR1B | P36896 | 2/20 | 0.40 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.40 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.36 |
| ▸ | PTGDR | Q13258 | 4/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.36 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.35 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.35 |
| ▸ | FEN1 | P39748 | 3/20 | 0.35 |
| ▸ | PLAT | P00750 | 1/20 | 0.34 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.34 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.34 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8347929 | 0.97 | TGFBR1 (0.40) | TGFBR1ACVR1BBMPR1AACVRL1ACVR1 | |
| SCHEMBL8347188 | 0.94 | TGFBR1 (0.43) | TGFBR1ACVR1BBMPR1AACVRL1ACVR1 | |
| SCHEMBL8346113 | 0.74 | PIM1 (0.38) | TGFBR1PRKD3PRKD1PRKD2 | |
| SCHEMBL13649319 | 0.74 | TGFBR1 (0.41) | TGFBR1ACVR1BBMPR1AACVRL1ACVR1 | |
| SCHEMBL8347937 | 0.73 | TGFBR1 (0.36) | TGFBR1ACVR1BACVRL1PROKR1PRKD3 | |
| SCHEMBL3838556 | 0.71 | TGFBR1 (0.47) | TGFBR1ACVR1BBMPR1AACVRL1ACVR1 | |
| SCHEMBL8347926 | 0.71 | TGFBR1 (0.41) | TGFBR1ACVR1BBMPR1AACVRL1ACVR1 | |
| SCHEMBL16879582 | 0.70 | TGFBR1 (0.57) | TGFBR1ACVR1BBMPR1AACVRL1ACVR1 | |
| SCHEMBL8344312 | 0.70 | MAPT (0.46) | TGFBR1ACVR1BACVRL1 | |
| SCHEMBL3838487 | 0.70 | PDE4D (0.36) | TGFBR1PRKD3PRKD1PRKD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9987277-B2 | Carboxamide 4-[(4-pyridyl)amino] pryimidines for the treatment of hepatitis C | JANSSEN SCIENCES IRELAND UC (IE) | 2018-06-05 | — | — | US | disclosed |
| US-9987277-B2 | Carboxamide 4-[(4-pyridyl)amino] pryimidines for the treatment of hepatitis C | JANSSEN SCIENCES IRELAND UC (IE) | 2018-06-05 | — | — | US | disclosed |
| US-9987277-B2 | Carboxamide 4-[(4-pyridyl)amino] pryimidines for the treatment of hepatitis C | JANSSEN SCIENCES IRELAND UC (IE) | 2018-06-05 | — | — | US | disclosed |
| EP-2097084-B1 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO] PYRIMIDINES FOR THE TREATMENT OF HEPATITIS C | JANSSEN R & D IRELAND (IE) | 2015-01-28 | — | — | EP | disclosed |
| EP-2097084-B1 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO] PYRIMIDINES FOR THE TREATMENT OF HEPATITIS C | JANSSEN R & D IRELAND (IE) | 2015-01-28 | — | — | EP | disclosed |
| US-20090247523-A1 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO]PYRIMIDINES USEFUL AS HCV INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2009-10-01 | — | — | US | disclosed |
| US-20090247523-A1 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO]PYRIMIDINES USEFUL AS HCV INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2009-10-01 | — | — | US | disclosed |
| US-20090247523-A1 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO]PYRIMIDINES USEFUL AS HCV INHIBITORS | JANSSEN SCIENCES IRELAND UC (IE) | 2009-10-01 | — | — | US | disclosed |
| EP-2097084-A2 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO] PYRIMIDINES FOR THE TREATMENT OF HEPATITIS C | Tibotec Pharmaceuticals Ltd. (IE) | 2009-09-09 | — | — | EP | disclosed |
| WO-2008040778-A2 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO] PYRIMIDINES FOR THE TREATMENT OF HEPATITIS C | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008040778-A2 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO] PYRIMIDINES FOR THE TREATMENT OF HEPATITIS C | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-04-10 | — | — | WO | disclosed |
| US-20060281763-A1 | Carboxamide inhibitors of TGFbeta | SCIOS INC. | 2006-12-14 | — | — | US | disclosed |
| WO-2006105222-A2 | CARBOXAMIDE INHIBITORS OF TGFB | SCIOS INC. (US) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247523-A1 | CARBOXAMIDE 4-[(4-PYRIDYL)AMINO]PYRIMIDINES USEFUL AS HCV INHIBITORS | HAVCR2, EIF2AK2, MAVS | TGFBR1 3765/4885ACVR1B 3981/4885BMPR1A 3796/4885 |
| US-20060281763-A1 | Carboxamide inhibitors of TGFbeta | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885ACVR1B 12/4885BMPR1A 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.